On November 18, Roche's Shanghai biopharmaceutical production base with an investment of 2.04 billion yuan was officially completed. The base has a construction area of about 25,000 square meters. It is Roche's second innovative drug production base in China. It is also the first base for a multinational pharmaceutical company to achieve localized production of macromolecular antibody biopharmaceuticals in China. According to the plan, the base will achieve localized sub-packaging of the ophthalmic monoclonal antibody drug Luoshijia by mid-2028, and fully implement aseptic filling production by the end of 2030.

Zhitongcaijing · 4d ago
On November 18, Roche's Shanghai biopharmaceutical production base with an investment of 2.04 billion yuan was officially completed. The base has a construction area of about 25,000 square meters. It is Roche's second innovative drug production base in China. It is also the first base for a multinational pharmaceutical company to achieve localized production of macromolecular antibody biopharmaceuticals in China. According to the plan, the base will achieve localized sub-packaging of the ophthalmic monoclonal antibody drug Luoshijia by mid-2028, and fully implement aseptic filling production by the end of 2030.